Inbrain Neuroelectronics

Inbrain Neuroelectronics is a pioneering private neurotech company developing a novel, graphene-based neural interface platform. Its core technology consists of flexible, high-density (up to 1024 contacts) brain-computer interfaces paired with an implantable neural processor and an AI-powered analytics platform, designed for closed-loop, personalized therapy. The company has achieved significant milestones, including FDA Breakthrough Device Designation for Parkinson's and the first human implant of its graphene BCI, positioning it at the forefront of advanced bioelectronic medicine. Backed by strategic collaborations with entities like Merck KGaA, Inbrain aims to address the vast unmet need in neurological disorders with less invasive, more precise therapies.

End-to-end neural platform combining flexible, high-resolution graphene-based brain-computer interfaces (BCIs), an implantable wireless neural processor, and an AI-powered data analytics platform for closed-loop, personalized neuroelectronic therapy.

Inbrain competes in the advanced neuromodulation space against large incumbents like Medtronic, Abbott, and Boston Scientific, as well as other neurotech startups such as Synchron, Paradromics, and Neuralink. Its primary competitive differentiation is the use of graphene for high-resolution, flexible interfaces enabling precise closed-loop therapy, a claim still undergoing clinical validation.